H.C. Wainwright initiated coverage of Incyte (INCY) with a Buy rating and $135 price target The current share price reflects Jakafi loss of exclusivity concerns versus the near-term catalysts “that can re-anchor post-Jakafi revenue assumptions over the next 12-18 months,” the analyst tells investors in a research note. The firm believes the loss of exclusivity math “is too extreme.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Tafasitamab-Parsaclisib Trial Termination Tempers Incyte Outlook
- Incyte price target raised to $116 from $115 at Barclays
- Incyte announces CHMP opinion recommending approval of Zynyz combination
- Intel upgraded, Domino’s downgraded: Wall Street’s top analyst calls
- Wells downgrades Incyte to Equal Weight on lack of catalysts